Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We RADNOR, Pa.–(BUSINESS The median major motor seizure frequency reduction from baseline in the OLE was 30.1%

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use. Cannabis and Anxiety. CBD for Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

JANUARY 3, 2022

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. We were able to rapidly incorporate the FDA’s feedback into the design of the current Phase 2 trial to make the data generated in Europe as relevant as possible for a potential future NDA submission. About Anebulo Pharmaceuticals, Inc. Rex Merchant.

Pharmaceutical 52

Pharmaceutical Cannabinoids Treatment Clinical Trials 52

NORML

MAY 26, 2020

The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain.

Clinical Trials 251

Clinical Trials Chronic Pain Cannabinoids Patients 251

Veriheal

AUGUST 12, 2021

Unlike “pharmaceutical CBD”—which contains zero traces of the psychoactive compound THC (tetrahydrocannabinol) and has been FDA-approved to treat Dravet syndrome and Lennox-Gastaut syndrome —artisanal CBD is non-mechanized and usually contains variable amounts of CBD and THC. It goes by the name of “artisanal CBD.” .

Epilepsy 66

Epilepsy Pharmaceutical Patients Sleep 66

Veriheal

FEBRUARY 21, 2023

Despite notable advances in MMJ research over the last decade, scientists have found that some states’ restrictions on qualifying conditions prevent millions of patients from getting the treatments they need—robbing them of potential relief offered by cannabinoid therapies.

Access 98

Access Patients Chronic Pain Conditions 98

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We believe the totality of the data is encouraging and supports advancing to Phase 3. Data Highlights. Patients who met eligibility criteria were able to continue ganaxolone treatment during a 24-week extension to the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. It has improved the quality of life for those dealing with chronic pain, nausea, seizures, and other medical conditions.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

Veriheal

SEPTEMBER 23, 2021

Fortunately, one such man, Levi Barker, provided us with some much-needed insight into what the substance is, how it is used in treatment, and more. Veriheal: What are some of the most common conditions you treat with iboga? All human conditions depend on healing physically, mentally, and spiritually.

Treatment 98

Treatment Medicine Research and Development Therapy 98

Cannabis Info

MARCH 2, 2019

Marijuana as a treatment for epilepsy. Medical cannabis is showing great potential in the treatment of epilepsy. Epilepsy is a neurological condition, that directly affects the nervous system and causes seizures in individuals who suffer from the condition. CONVENTIONAL TREATMENT. CANNABIS AS A POTENTIAL TREATMENT.

Epilepsy 69

Epilepsy Treatment Marijuana Research and Development 69

Veriheal

JANUARY 26, 2023

Bipolar disorder is a complex condition that impacts millions worldwide, leading to extreme mood swings, intense emotional episodes, and difficulty managing day-to-day life. Most commonly, pharmaceutical medication is prescribed to regulate moods. But there may be some good news for those coping with this mental health issue.

Treatment 98

Treatment Cannabinoids Conditions Pharmaceutical 98

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. However, with the database not yet available to the nation’s private clinics there are concerns over the quality and volume of data it will garner.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

NOVEMBER 12, 2021

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. In compliance with current Good Manufacturing Practice requirements, the Company delivered ANEB-001’s active pharmaceutical ingredient to its contract manufacturer to fill into 10 mg and 50 mg capsules for finished product. About Anebulo Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Research and Development 52

The Cannigma

FEBRUARY 1, 2023

Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. Work together to weigh the potential benefits and risks specific to your medical condition, and track the progress of your cancer along with your cannabis regimen. 1 So can cannabis cure cancer?

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Puff Puff Post

DECEMBER 28, 2018

An official study is aimed to conclude in July of 2019, where we’ll see all the data which comes forth. Influencing how information is processed and how nerve cells and synapses in the brain interact, the exact function related to autism is still not well understood, and no pharmaceuticals around yet can ‘fix’ autism.

Treatment 76

Treatment Oil CBD Therapy 76

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Some parents, who have travelled to the Netherlands to buy cannabis medicines, feel the treatment will not help many children because it does not contain THC, which they argue has helped their children. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Veriheal

JUNE 17, 2022

Cannabis is being increasingly chosen as an alternative to pharmaceutical medication, specifically those like opioids that are intended to reduce pain. Specifically, almost half of the participants completely stopped using analgesic medication following six months of medical cannabis treatment. Moving Toward MMJ in Cancer Treatment.

Patients 98

Patients Treatment Pharmaceutical Consumption 98

Veriheal

JULY 12, 2021

As a veteran, being able to get past the PTSD involves transitioning out of the mental and emotional war zone, which is challenging and the reason why veterans seek out multiple methods to deal with the condition. At this time, there is little in the way for combat-related PTSD treatment specifically.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

AUGUST 3, 2021

Many mental health disorders have treatment options, but they aren’t nearly as safe and efficacious as conventional pharmaceuticals or therapies. CSE: MXT) (OTCQB: MXTTF) aims to address these problems by pairing biometric interviews with brainwave data to create a proprietary mental health reference database.

Research and Development 105

Research and Development Data Conditions Therapy 105

The Cannigma

NOVEMBER 23, 2021

Listen & Subscribe: Finding the correct dosage and combination of cannabinoid products for medical treatment is almost universally a long and expensive process of trial and error. The app helps patients make sense of their journey by simplifying the information and supplying data-driven insights into their regimen and its effects.

Data 52

Data Patients Access Wellness and Beauty 52

Cannabis Law Report

JANUARY 16, 2022

Malaysia’s National Pharmaceutical Regulatory Agency (NPRA) previously approved a prescription medicine derived from cannabis in 2014 to treat muscle spasms and spasticity from multiple sclerosis. Sativex was developed by GW Pharmaceuticals, a maker of cannabinoid therapeutics based in Ireland.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Recruitment for the Phase 2 trial will begin immediately, and efficacy data is expected by the end of first quarter of 2022. “To MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

AUGUST 18, 2022

Among the first in the nation, Phillips Lytle’s Psychedelics Practice Team combines expertise in pharmaceutical science, FDA regulations and risk management to serve the legal needs of emerging bio-tech sectors. Promising research in psychedelics as a mental health treatment accelerates growth of industry in need of legal counsel.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Forward-Looking Statements.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

SEPTEMBER 21, 2023

Now that the monsoon rains are in full swing, the heat and rain provide the perfect breeding condition for the amphibians. However, this year had an anomaly because the monsoon’s first conditions kicked in on July 17 , alongside a record-breaking temperature. 15 every year. You’ll be hearing more of the croaking often.”

Clinical Trials 113

Clinical Trials Therapy Conditions Pets 113

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. ” Study 755-101-HV is a randomized, vehicle controlled, double-blind, Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment period as part of a randomized, vehicle controlled, double-blind, Phase 1 trial.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

JUNE 19, 2023

The psychedelic drugs here include LSD, MDMA, psilocybin, ketamine, and ayahuasca, which are in high demand for mental health treatment and other therapeutic reasons. All the data provided by the report are validated and trustworthy and can be used to gain the upper hand in the industry. billion in the next six years.

Therapy 109

Therapy Treatment Patients Policy 109

CannaMD

NOVEMBER 22, 2020

For those who suffer from migraine pain, the excruciating condition can be completely debilitating, impossible to manage without a dark room, a cool cloth over the eyes, and sublime silence. Patients used the app, Strainprint, which allowed data to be archived and studied. and migraine severity by 49.6%. Find Out if You Qualify.

Marijuana 116

Marijuana Treatment Patients Cannabinoids 116

Cannabis Law Report

JUNE 19, 2022

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

AUGUST 2, 2021

The nearly 3,000 participant study will capture and publish the most comprehensive data ever collected on CBD product effectiveness from 13 commercially available U.S. Radicle ACES is Institutional Review Board (IRB) approved and will capture CBD effectiveness data directly from nearly 3,000 study participants.

CBD 105

CBD Data Sleep Clinical Trials 105

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

Cannabis Law Report

JUNE 23, 2021

. “We are excited to be initiating our pilot program with Medicann in Jersey, which represents a unique, ‘ring-fenced’ environment for establishing potentially numerous studies on the efficacy of treatments using plant-based therapies. About RYAH Group, Inc. RYAH Group, Inc. Forward-Looking Statements.

Programs 100

Programs Data Events Collective 100

Veriheal

OCTOBER 29, 2020

Is the focus on the negative impact due to the fact that role players want cannabis to remain illicit as to avoid its potential role in replacing pharmaceutical medication? The data for this graphic was provided by Jim Hudson at Hellth.com. . Scenario 2: Pharmaceuticals. However, the focus of funding remains on negative impacts.

Pharmaceutical 98

Pharmaceutical Therapy Cannabinoids Chronic Pain 98

Cannabis Law Report

JULY 12, 2019

Ultimately, the cannabinoid system works by way of multiple molecules affecting multiple receptors at once – the entourage effect, and thus such singular approaches to treatment by way of the cannabinoid system are not effective. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73